Resources for pharmacy program members

www.vizientinc.com/PharmacySolutions

We are here to help

Visit our pharmacy webpage for webbased resources and the latest updates

Log into My Dashboard on our website to access

Contact us at PharmacyQuestions@vizientinc.com







Pharmacy Solutions

Sourcing, clinical and ambulatory support



Analytics

Drug spend and clinical analytics platform



Consulting Services

Operations, ambulatory, 340B, clinical



Aggregation Groups

Pharmacy group purchasing & oncology network





Navigating Vizient Pharmacy Analytics with Pharmacy Market Outlook projections and data



March 27, 2024

Gain expert insights for pharmacy planning A webinar series exploring new and hot topics from the recently published Pharmacy Market Outlook

Navigating Vizient Pharmacy Analytics with PMO projections and data

March 27, 1 p.m. CT

Learn about the features and benefits of our new Pharmacy Portal and rebranded Pharmacy Analytics platform (formerly Vizient Savings Actualyzer – Pharmacy)

TODAY!

Cell & gene therapy and specialty pharmaceuticals

April 24, 1 p.m. CT

There are 170+ gene and cellular immunotherapy products in the pipeline.

Find out more about the novelty of gene therapy and the challenges it presents





vizient

3 Winter 2024 Pharmacy Market Outlook Confidential Information

Learn more and register at vizientinc.com/events


Housekeeping

- This call is being recorded
- Because of the large number of participants, all lines will be kept in listen-only mode
- Questions will be managed through the Q & A box





Access and download



Visit the Pharmacy Market Outlook webpage where you can access and download the report as well as



info.vizientinc.com/ pharmacy-marketoutlook-memberdetails

Contact PharmacyQuestions@vizientinc.com

Also from this page...

Access the latest Budget Impact **Projections** report related to the healthcare supply chain







Read our new trends report and learn about strategies to grow revenue



- Real-time purchasing oversight
- Ability to customize views and schedule reports
- Insights and reporting into drug shortages, controlled medication, essential medications, biosimilars and more
- Data down to invoice level detail for a rolling 24 months

Vizient Pharmacy Analytics Formerly Savings Actualyzer – Pharmacy (VSAP)

Now available!

- **Pharmacy Portal**: New user-friendly interface allowing a singular access point for pharmacy services and reporting
- **Pharmacy Analytics**: Available from the Pharmacy Portal with a new look and capabilities in addition to your favorite existing reports

Training: Experience the new tools and ask questions of our analytics experts



Select a session that works for you

vizientinc.com/learningcenter/pharmacy-analytics-resources **Webinar**: Insights into emerging trends and success stories for Pharmacy Analytics

May 14, 1-2pm CT





Contact PharmacyQuestions@vizientinc.com

Today's presenters



Jeni Hayes, PharmD, MS, BCPS Sr Clinical Manager, Market Intelligence



Richard Ponder, MBA, CMRP, CPhT, CPP, CEPP, PMC-VIII

AVP, Spend Insights and Services



Projected drug price inflation July 1, 2024 through June 30, 2025

This is our highest projected inflation rate since the July 2019 edition (January 2020 – December 2020 prediction window)

Several factors drive the trend of increasing inflation:

- Increase in specialty and ultra-specialty approvals
- Additional indications for previously approved medications, increasing utilization
- Products with higher-than-customary price increases
- Payer restrictions influencing site of care and class of trade implications for pharmacy services





Vizient Pharmacy Analytics

With daily data feeds from 20+ distributors, Vizient pharmacy insights begin with visibility into \$130B+ in member spend (GPO eligible, 340B and WAC) across acute and non-acute care settings

Pharmacy program participants gain access to the Pharmacy Portal and Pharmacy Analytics as part of their Vizient pharmacy GPO participation


- Real-time purchasing oversight on a user-friendly interface
- Ability to customize views and schedule reports
- Insights and reporting into drug shortages, controlled medication, essential medications, hazardous medications, biosimilars, anesthesia gases and more
- Data down to invoice level detail for a rolling 24 months

- Category insights
- Market intelligence
- Contract optimization
- Program compliance
- Price assurance
- Access to expert resource



Before Savings Actualyzer – Pharmacy (VSAP)

- Accessing took you to the Actualyzer platform dashboard
- From there, you would click on various reporting links to access information



vizient

Savings Actualyzer Pharmacy



. 0 .


Now Access Pharmacy Analytics from the Pharmacy Portal

Step 1: Log in to My Dashboard on our website vizientinc.com

Step 2: Refer to Quick Links to find your available solutions


Step 3: Select the performance tile for Pharmacy Portal

If you need assistance, contact Member Support at <u>VizientSupport@vizientinc.com</u>



Pharmacy Portal & Pharmacy Analytics

- New integrated experience from the portal
- Portal displays performance tiles that provide high-level metrics and key performance indicators
- Use the system selection menu at the top left to select from your available systems and facilities



Category insights

Insights & intelligence

Baseline Identifie Jul-2023 - Sep		\$128,304,95	0			
Comparative Identi	fied Spe	\$22,905,75	5	\$1,649,638	\$16,36	\$3,054 \$303,371 \$17,657,197
Total PQM In	spect	(\$105,399,24	0)	91,049,635 Price	310,00 Our	
954 NDCs with Spen 8,257 NDCs with Spen		+\$822,235 (\$106,021,47				
View Top 10 \sim by	Brand Name	√ for	AI NDC's		View D	etalls
irand Name	Total PQM Impact	Price Change	Gty Change	Started Buying	Stopped Buying	Total Spend Total Spend July 2023 - Step-2023 Cel-2023 - Dec-2023
ROLIA	(\$1,388,062)	(\$137,250)	(\$1,250,811)			
ERVOY	(\$1,710,448)	+\$143,277	(\$1,196,222)		(9990,501)	TRIKAFTA \$15,028,545
OURIS	(\$1,713,710)	(\$133.034)	(\$1,580,684)			KEYTRUDA \$2,033,025
NTYVIO	(\$1,802,781)	+\$104,709	(\$1,967,490)			62,000,920
IDLGENSMA	(\$2.254.412)				(\$2,254,412)	DCREVUS 8575,303
ARZALEX FASPRO	(\$2,059,901)	(\$159,003)	(\$2,700,095)			OPDIVO \$4,292,425
POIVO	(\$3,647,940)	+\$35,244	(\$3,604,293)			53, 535, 457
CREVUS	(\$4,205,710)	(\$102.330)	(\$4,153,379)			00/0,400
EYTRUDA	(\$7,805,677)	(\$307,504)	(\$7,558,173)			ZOLGENSMA \$2,254,412
RIKAFTA	(\$13,047,391)	(\$191,630)	(\$12,354,520)		(\$501,341)	ENTYVIO \$2,148,072 5290,281
bal	(\$40,616,126)	(\$744,201)	(\$36,455,671)		(\$3,416,256)	BOLLIFIE \$1,098,000 BOLLIFIE \$1,098,000 ISA4,192 VERVOV \$50,191 PROLIA \$20,470 \$1,672,832 \$20,470
View Top 10 🗸 by	Manufacturer Name	 ✓ for 	AII NDC's		View D	etais
fanufacturer Name	Total PQM Impact	Price Change	Gty Change	Started Buying	Stopped Buying	Total Spend Total Spend Jul 2023 - Teen 2023 Cott 2023 - Dan 2023
IENZYME	(\$2.014.191	+\$111.325	(\$708.703)		(\$1,356,753)	AP-max - sep-max DE-2023 - De-2023
GTRAZENECA	(\$2,039,455)	(\$8,422)	(\$1,937,990)	+5750	(\$93,900)	VERTEX PHARMACE \$17,018,008
EAGEN INC.	(52.225.052	(5004.778)	(\$1.421.176			32,745,800

- Market changes
- Provider vs. Market insights
- Trends, shifts, and shortages

Opportunity Identification & Benchmarking

Your System	
PSM Demo Panent - 3270853	
Price Index Insights Price Index	x Rankling Insights
	arest 10 HCO by Opportunity Spend 0
Class of Trade	Therapeutic Class Enhanced
Acute Care 🗸	AL V
3.70 6.21 20.71	Legent Rute Name Prior HCD Price Index
HCD Price Index Opportunity Spend HCO 3.73 \$473,941,966 HCO 3.94 \$475,291,792	
Non Fill Fill How HCO 5.21 5451,303,642 HCO 5.27 5423,348,843 HCO 7.15 5423,342,343 HCO 5.42 5432,342,343	· · · · · · · · · · · · · · · · · · ·
HCO 9.65 5485.124.838	ALC: ALC: ALC: ALC: ALC: ALC: ALC: ALC:
HC0 15.67 \$411,694,347	
HCO 17.10 \$405,400,637	and and a set of the s
HCO 18.52 \$384,309,920	W M M M M
HCO 20.71 5385.982.456	under had a set of the
	Records New Released
View by The results One Extransf	Therapeutic Class Enhanced
Therapeutic Class Enhanced	# V

- Formulary alignment
- Benchmarking & peer compare
- Market share mix

Margin Management & Monitoring

ystem			Facility			0	uarter	
SM Demo Parent - 3270853			Al			~ A	4	
Summary	Details							
liew by								
Facility Name	\sim							
Potential Max CM	C Daimburgamar	t hu Escilitu	Botor	tial Max (MS Reimbursem	ant hu Ouartar		
Name	3 Neimbursemei	it by Fability						
Facility Name	Potential Max	Potential Total Net	Potent 5.0.1bs	ial Max CMS Ra	inbursement ePotential Ti	stal Net Revenue After Drug E	irpense	
	CMS Reimbursement	Revenue After Drug Expense				_		
PSM Demo Child 2	\$ 26,305,645	-5 20,466,035	\$1004			\$ 0.09bm		
PSM Demo Child 3	\$ 17,095,452	-5 49,858,807	3 0 0 0 1					
PSM Demo Child 1	5 11,323,458	-5 15,225,192				-\$ 0.10m		
PSM Demo Parent	\$ 4,752,722	-87,725,670	-\$0.1bs					
Total	\$ 59,557,277	-\$ 101,274,600						
						Q2-2023		
			Top 1	0 NDCs w	th Highest Lowest	Potential Revenue	After Drug Ex	pense
			- i i i i i i i i i i i i i i i i i i i		_			
			3-Code	NDC Number	NDC Description		Potential Max CMS Reimbursement	Potential Total N Revenue After Drug Expense
			.12353	00078082581	SANDOSTATIN LAR DEP	OT (octreotide acetate, mic	\$ 601,339	\$ 332.0
			39281	72493010303	JELMYTO (mitomycin) 40	ing x 2 KIT 1 X 1 CT KIT 0	\$ 231,838	\$ 109,5
			J2907	75657008010	KRYSTEXXA (pegioticas)	Bright VAL 1X 1ML VI.	\$ 75,845	\$ 76,8

- Reimbursement
- Program compliance
- Contract optimization



Price assurance Price Verification & Price Leveling

Vizient *contracted* products: **Six layers** of automated price verification service



Non-Vizient contracted products

- Parity in pricing across all account types
- **Price Leveling** Within same class of trade, identifies variation in pricing

		Explorer			Monitor			Toolbox					
ata Systems/F	Facilities Selection	PSM Demo Parent X											
< Back to report	PRICE LEVELING	BY GENERIC NAME											Ŧ
PNEUMOCOG	CCAL 20-VALENT CON	JUGATE VACCINE											\$4,599,8
		PEMBROLIZUMAB								\$3,256,537			
	ANTI-THYMOCYT	E GLOBULIN, RABBIT						\$2	740,243				
	SU	SAMMADEX SODIUM						\$2,462,595					
HUMAN	PAPILLOMAVIRUS VA							\$2,341,185					
		DENOSUMAB					5	2.209.959					
PNELIMOCO	CCAL 13-VALENT CON						\$1,876,570						
	-ZOSTER VIRUS GLYC						8.058						
WARUCELLA.	LOGIER VIRUS GLYC	NIVOLUMAB					48,058 94,431						
	DARATUMUMAB-HY	ALURONIDASE-FIHJ				\$1,6							
		REMDESIVIR				\$1,528,622							
IMMUNE GL	OBULIN, GAMM(IGG)/G					\$1,513,810							
		DINUTUXIMAB				\$1,450,859							
DIPHTHERIA	A PERTUSSIS(ACELLU	ILAR), TETANUS VA			\$	\$1,337,833							
		BUROSUMAB-TWZA			\$1,167	516							
		INFLIXIMAB-DYYB			\$1,137,0	004							
		RITUXIMAB-PVVR			\$1,124,4	00							
		PEGFILGRASTIM			\$1,084,17	7							
Back to report	PHARMACY BREAKDOWN												
Facility Name	Distributor Account Name	e Distributor Account Number	-										
Facility Name PSM Demo Child 1	Distributor Account Name	2052038410	GPO	Cardinal Health Inc	\$ 2,300.21	09/30/2023	5.00	\$21,430	50	50	50	\$21,430	
Facility Name PSM Demo Child 1 PSM Demo Child 1	Distributor Account Name PSM DEMO CHILD 1 PSM DEMO CHILD 1	2052038410 2052039148	GPO GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,380.21	09/30/2023 09/30/2023	5.00 5.00	521,430 \$16,668	50 50	50 50	50 50	521,430 \$16,668	
Facility Name PSM Demo Child 1 PSM Demo Child 1 PSM Demo Child 2	Distributor Account Name PSM DEMO CHILD 1 PSM DEMO CHILD 1 PSM DEMO CHILD 2	2052030410 2052030148 2057202085	GPO GPO GPO	Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,380.21 \$ 2,355.88	09/30/2023 09/30/2023 01/31/2023	5.00 5.00 2.18	\$21,430 \$16,668 \$2,356	50 50 50	50 50 50	50 50 50	521,430 \$16,668 \$0	
Facility Name PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2	Distributor Account Name PSM DEMO CHED 1 PSM DEMO CHED 1 PSM DEMO CHED 2 PSM DEMO CHED 2	2052038410 2052039148 2057202085 2052038422	GPO GPO GPO GPO	Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc	\$ 2,300 21 \$ 2,380 21 \$ 2,355 88 \$ 2,350 21	09/30/2023 09/30/2023 01/31/2023 09/30/2023	5.00 5.00 2.18 5.00	\$21,430 \$16,668 \$2,356 \$349,635	50 50 50 50	50 50 50 50	50 50 50 50	521,430 516,668 50 5349,635	
Facility Name PSM Demo Child 1 PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 2	Distributor Account Name PSM DEMO CHILD 1 PSM DEMO CHILD 1 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 2	2052038410 2052039148 2057202085 2052038422 2052039252	GPO GPO GPO GPO GPO	Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,300.21 \$ 2,355.88 \$ 2,300.21 \$ 2,300.21	09/30/2023 09/30/2023 01/31/2023 09/30/2023 09/30/2023	5.00 5.00 2.18 5.00 5.00	521,430 516,668 52,356 5349,635 533,219	50 50 50 50 50	50 50 50 50 50	50 50 50 50 50	521,430 \$16,668 50 \$349,635 \$33,219	
Facility Name PSM Demo Child 1 PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 3	Distributor Account Name PSM DEMO CHLD 1 PSM DEMO CHLD 1 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 3	2052038410 2052039148 2057202005 2052038422 2052039252 2052039252	GP0 GP0 GP0 GP0 GP0 GP0 GP0	Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,300.21 \$ 2,355.88 \$ 2,300.21 \$ 2,300.21 \$ 2,300.21 \$ 2,358.38	09/30/2023 09/30/2023 01/31/2023 09/30/2023 09/30/2023 12/31/2022	5.00 5.00 2.18 5.00 5.00 2.47	\$21,430 \$16,668 \$2,356 \$348,635 \$33,219 \$252,346	50 50 50 50 50 50	50 50 50 50 50 50	50 50 50 50 50 50	521,430 516,668 50 5349,635 533,219 50	
Facility Name PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 3 PSM Demo Child 3	Distributor Account Name PSM DEINO CHILD 1 PSM DEINO CHILD 1 PSM DEINO CHILD 2 PSM DEINO CHILD 2 PSM DEINO CHILD 2 PSM DEINO CHILD 3	2052030410 2052039148 2057202005 20520304/22 2052030/252 2052030252 2052030192 2052040900	GP0 GP0 GP0 GP0 GP0 GP0 GP0 GP0	Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc Cardinal Health Inc	\$ 2,300 21 \$ 2,380 21 \$ 2,385 38 \$ 2,385 38 \$ 2,300 21 \$ 2,358 38 \$ 2,358 38 \$ 2,350 21	0930(2023 0939(2023 0131(2023 0630(2023 0630(2023 12(31/2022 0631(2023	5.00 5.00 2.18 5.00 5.00 2.47 5.00	\$21,430 \$16,668 \$2,356 \$349,635 \$33,219 \$252,346 \$4,739	50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50	521,430 \$16,668 50 \$349,635 \$33,219 \$0 \$4,739	
Facility Name PSM Demo Child 1 PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 3 PSM Demo Child 3 PSM Demo Child 3	Distributor Account Name PSM DEMO CHILD 1 PSM DEMO CHILD 1 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 3 PSM DEMO CHILD 3 PSM DEMO CHILD 3	2052030410 2052030140 2057202085 20520302422 2052030252 20520301925 2052030192 2052030192 2052030453	GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300,21 \$ 2,380,21 \$ 2,356,80 \$ 2,350,21 \$ 2,350,21 \$ 2,350,21 \$ 2,350,21 \$ 2,350,21	0930(2023 0939(2023 0131(2023 0939(2023 0939(2023 12(31(2022 08(31(2023 0939(2023	5.00 5.00 2.18 5.00 5.00 2.47 5.00 5.00 5.00	521,430 516,668 52,356 5348,635 533,219 5252,346 54,739 53,346,771	50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50	521,430 516,668 90 5349,635 533,219 50 54,739 53,346,771	
Facility Name PSM Demo Child 1 PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 3 PSM Demo Child 3 PSM Demo Child 3	Distributor Account Name PSM DEMO CHLD 1 PSM DEMO CHLD 1 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 3 PSM DEMO CHLD 3 PSM DEMO CHLD 3	2052030410 2052030148 205703045 2052030422 2052030422 2052030422 20520301925 2052030192 2052030453 20527195366	GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,300.21 \$ 2,356.80 \$ 2,300.21 \$ 2,300.21 \$ 2,300.21 \$ 2,350.38 \$ 2,300.21 \$ 2,350.21 \$ 2,350.21 \$ 2,350.21	08/30/2023 08/30/2023 01/51/2023 06/30/2023 09/30/2023 08/31/2023 09/30/2023 09/30/2023	5.00 5.00 2.18 5.00 5.00 2.47 5.00 5.00 5.00	521,430 516,668 52,356 5348,635 533,219 5252,346 54,739 53,346,771 5104,701	50 50 50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50	\$21,430 316,668 50 \$349,635 \$33,219 50 \$4,739 \$3,346,771 \$104,701	
Facility Name PSM Demo Child 1 PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 3	Distributor Account Name PSM DEMO CHLD 1 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 3 PSM DEMO CHLD 3 PSM DEMO CHLD 3 PSM DEMO CHLD 3 PSM DEMO CHLD 3	2052038410 2052039148 2052702005 20520394822 2052039452 2052039192 2052039192 2052039453 2052706653 2057705566 205770566	GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,300.21 \$ 2,356.80 \$ 2,300.21 \$ 2,300.21 \$ 2,300.21 \$ 2,358.38 \$ 2,300.21 \$ 2,350.21 \$ 2,300.21 \$ 2,300.21 \$ 2,300.21	09/0/2023 09/0/2023 01/0/2023 09/0/2023 09/0/2023 09/0/2023 09/0/2023 09/0/2023 09/0/2023 09/0/2023	5.00 5.00 2.15 5.00 5.00 2.47 5.00 5.00 5.00 5.00	\$21,430 \$16,665 \$2,356 \$332,219 \$252,346 \$4,730 \$3,344,771 \$104,701 \$209,414	50 50 50 50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50	521,430 516,668 90 5349,635 533,219 50 54,739 53,346,771 5104,701 5209,414	
Facility Name PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 3	Distributor Account Name PSM DEMO CHILD 1 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 3 PSM DEMO CHILD 3	2052030410 2052039440 2057202005 2052039482 2052039482 2052039482 2052039482 2052039453 2052036453 2057206530 2057206530 2150738711	GPO GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21 \$ 2,380.21	09/30/2023 09/30/2023 01/31/2023 09/30/2023 09/30/2023 00/31/2022 09/30/2023 09/30/2023 09/30/2023 09/30/2023	5.00 5.00 2.15 5.00 5.00 2.47 5.00 5.00 5.00 5.00 5.00 5.00	521,430 546,668 52,356 5346,635 533,219 5252,346 547,739 53,346,771 5104,771 5104,771 5104,701 5209,414 5409,069	50 50 50 50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50 50	521,430 516,668 59 5349,635 533,219 50 54,739 53,346,771 5104,701 5104,701 5209,414 5409,069	
Facility Name PSM Deeno Child 1 PSM Deeno Child 2 PSM Deeno Child 2 PSM Deeno Child 2 PSM Deeno Child 3 PSM Deeno Child	Distributor Account Name PSM DEMO CHILD 1 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 3 PSM DEMO CHILD 3	2052030410 2052039440 2052039440 20520392045 2052039252 2052039422 2052039492 2052039492 2052039453 20527195368 20527195368 20527195368	GPO GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,380.21 \$ 2,38	09302023 09302023 01312023 09302023 120102023 09302023 09302023 09302023 09302023 09302023 09302023 09502023	5.00 2.18 5.00 5.00 2.47 5.00 5.00 5.00 5.00 5.00 5.00 2.47	521,430 516,660 53,350 53,40,635 53,340,635 53,340,731 53,346,771 5104,701 5209,444 5400,009 54,717	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 50 50 50 50 50 50 50 50 50 50	50 50 50 50 50 50 50 50 50 50 50 50	521,430 516,668 5340,635 533,219 50 53,346,771 510,771 510,771 510,771 5209,414 5409,669 50	
Facility Name P5M Demo Child 1 P5M Demo Child 2 P5M Demo Child 2 P5M Demo Child 3 P5M Demo Parent P5M Demo Parent	Distributor Account Nami PSM DEMO CHLD 1 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 3 PSM DEMO CHLD 3	2052038410 205203948 2057202055 2052039422 2052039422 2052039492 2052039492 2052039493 20557206630 21597206630 21597206630 21597219586 20557206630 21597219 2052039243	- GPO GPO GPO GPO GPO GPO GPO GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300.21 \$ 2,380.21	0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 1231/2022 0228/2023	5.00 2.18 5.00 5.00 2.47 5.00 5.00 5.00 5.00 5.00 5.00 2.47 2.18	521,430 536,663 536,635 533,249 532,249 532,246 54,739 533,346,771 5164,701 5209,414 5409,669 54,717 57,070	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 50 50 50 50 50 50 50 50 50 50 50	521,430 516,665 50 5346,635 5346,635 533,219 50 54,739 53,346,771 5104,701 5209,414 5409,669 50 50	
Facility Name PSM Demo Chid 1 PSM Demo Chid 2 PSM Demo Chid 2 PSM Demo Chid 3 PSM Demo Parent PSM Demo Parent	Distributor Account Name PMD DEMO CHILD 1 PSM DEMO CHILD 1 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 2 PSM DEMO CHILD 3 PSM DEMO REAT	2052038410 205203940 2057212025 2057212025 205203942 205203942 205203942 205203942 205203942 2052139453 2057116356 2057116356 2057116 205203949 205203949	- GPO GPO GPO GPO GPO GPO GPO GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300 21 \$ 2,300 21 \$ 2,355,40 \$ 2,300 21 \$ 2,305,80 \$ 2,205,80 \$ 2,20	0530/2023 0530/2023 0531/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023 0530/2023	5.00 2.18 5.00 5.00 2.47 5.00 5.00 5.00 5.00 5.00 5.00 2.47	521,430 536,665 538,635 533,219 5252,346 54,739 53,34,771 5194,771 5209,414 5409,069 54,717 57,070 52,606	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 50 50 50 50 50 50 50 50 50 50 50 5	521,430 516,665 50 5349,635 5349,635 533,219 50 54,739 53,346,771 5104,701 5303,414 5409,069 50 50 50	
Facility Name PSM Demo Child 1 PSM Demo Child 1 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 2 PSM Demo Child 3 PSM Demo Parent PSM Demo Parent PSM Demo Child 2 PSM Demo Ch	Distributor Account Nami PSM DEMO CHLD 1 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 2 PSM DEMO CHLD 3 PSM DEMO CHLD 3	2052038410 205203948 2057202055 2052039422 2052039422 2052039492 2052039492 2052039493 20557206630 21597206630 21597206630 21597219586 20557206630 21597219 2052039243	- GPO GPO GPO GPO GPO GPO GPO GPO	Cardinal Health Inc Cardinal Health Inc	\$ 2,300 21 \$ 2,400 5 \$ 3	0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 0930/2023 1231/2022 0228/2023	5.00 2.18 5.00 5.00 2.47 5.00 5.00 5.00 5.00 5.00 5.00 2.47 2.18	521,430 536,663 536,635 533,249 532,249 532,246 54,739 533,346,771 5164,701 5209,414 5409,669 54,717 57,070	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 50 50 50 50 50 50 50 50 50 50 50 5	50 50 50 50 50 50 50 50 50 50 50 50 50	521,430 516,665 50 5346,635 5346,635 533,219 50 54,739 53,346,771 5104,701 5209,414 5409,669 50 50	en of Sample



Supply assurance Drug Shortage Insights report

	Drug Shortage Alternative Products												
	Shortage Status Generic All V All	Name ~	All P	roducts	Purchas	sed Products	Not Purchased Products						
	Drug Shortage by Generic Name			Grid		Spend	# of NDCs on Shortage 로 요 …						
	Generic Name	Shortage Status	Shortage Start Date	Last Revised Date	# of NDCs on Shortage	Spend	Sold Qty Ordered Qty						
	FLUTICASONE PROPIONATE	Resolved	3/30/2020	1/26/2024	8	\$ 55.313.345	329.204 439.958						
	IDARUBICIN HCL	Active	12/15/2023	Drug Sh	ortage by NI	DC					NDC	ND	C Details
		Active	7/10/2015 5/16/2018	A NDC Number			NDC December	Charless	Chasteres	Lest Devland	Encod	Fald Ote	- 5 ÷
	RANITIDINE HCL	No Longer Available	5/16/2018	4 NDC Number			NDC Description	Shortage Status	Shortage Start Date	Last Revised Date	Spend •	Sold Qty	Ordered Qty
	SODIUM ACETATE	Active	9/1/2021				20 ML VIAL MUV, OUTER	Active	2/7/2018	3/4/2024	\$ 4,519,713	29,516	
<i>c</i>		Resolved	12/30/2016	14			5 ML VIAL MUV, OUTER 10 ML VIAL OUTER, MDV	Active	2/7/2018 2/7/2018	3/4/2024	\$ 1,547,778 \$ 713.834	21,324 13,134	
$\lambda / $	al almost also atta as a	Resolved	7/26/2018	5			5 ML VIAL OUTER, MDV	Active	2/7/2018	3/4/2024	\$ 575.392	4,945	30,737
 view identifie 	d drug shortages,						10 ML VIAL MUV, OUTER	Active	2/7/2018	3/4/2024	\$ 429,492	8,793	
				42023011310	KETALAR (ketami	ine HCI) 10mg/mL VI	AL 10 X 20 ML VIAL STERI-VIAL, MUV	Active	2/7/2018	3/4/2024	\$ 235,889	1,253	25,014
including impa	acted NDCS			55150044010	KETAMINE HCL	100mg/mL VIAL 10 X	10 ML VIAL MUV, OUTER	Active	2/7/2018	3/4/2024	\$ 6,818	56	6,516
0 1				42023011410	KETALAR (ketami	ine HCI) 50mg/mL VI	AL 10 X 10 ML VIAL 10'S,MDV	Active	2/7/2018	3/4/2024	\$ 3,466	49	25,237
 Gain insight c resupply estir 						-	rtage Reasons below:						
				Shortage R	• Hi • My • Pa	ikma has ketamine inj ylan Institutional dive ar has Ketalar on bacl	s ketamine on shortage due to increased demand. ection on back order due to shortage of active ingredient. sted ketamine to AuroMedics. « order due to shortage of active ingredient. shortage due to manufacturing delays.						
 Identify when and its status 	a shortage began	J		Resupply Esti	nate Note(s) inte - Hi - Pa	ugia has ketamine 50 mittent back order au ikma has ketamine 10 ar has all Ketalar pres	mg/mL 10 mL vials and 100 mg/mL 10 mL vials on long-term of the company is releasing product as it becomes available 0 mg/mL 5 mL vials and 56 mg/mL 10 mL, vials on allocation entations on long-term back order and the company cannot will vials on back order and the company estimate	estimate a release dat	0.				



Supply assurance Drug Shortage Insights

View alternative equivalent products with recent supply in distribution channel

Generic Dr		C Number - Description				Drug S	Shortage
KETAMINE I	HCL VIAL V AII V AII				~	□ N	
Products	3			∓ 63 ···	Product Ca Supply Streng		0
NDC Number	NDC Description	Generic Drug Name	Manufacturer Name	Drug Shortage			н
00143950801	KETAMINE HCL 50mg/mL VIAL 1 X 10 ML VIAL INNER, MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	N			
00143950810	KETAMINE HCL 50mg/mL VIAL 10 X 10 ML VIAL OUTER, MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	Y		Mo	derately H
0143950901	KETAMINE HCL 100mg/mL VIAL 1 X 5 ML VIAL INNER, MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	Ν			
0143950910	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL OUTER, MDV	KETAMINE HCL VIAL	WEST-WARD/HIKMA	Υ			
0409004005	KETAMINE HCL 100mg/mL VIAL 1 X 5 ML VIAL MUV, INNER	KETAMINE HCL VIAL	HOSPIRA-NOVAPLU	N			Mode
0409004010	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA-NOVAPLU	Ν			
0409205105	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	Υ			
0409205115	KETAMINE HCL 100mg/mL VIAL 1 X 5 ML VIAL MUV, INNER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	Ν			
0409205310	KETAMINE HCL 50mg/mL VIAL 10 X 10 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	Y			N
0409205320	KETAMINE HCL 50mg/mL VIAL 1 X 10 ML VIAL MUV, INNER	KETAMINE HCL VIAL	HOSPIRA/PFIZER	Ν			N
	ve Equivalent Products ecent Supply in Distribution Channel ric Name Alt Manufacturer Name	On Viz Contract Pkg S		NES	r 🗆		
H NDC	All NDC Description	Alt Canadia Drug Marco	A 16 B.8	On 14-	Die Cine M. Ci	NEC	NES-
lt NDC lumber	Alt NDC Description	Alt Generic Drug Name	Alt Manufacturer Name	On Viz Contrac	Pkg Size N+ Fla t Match	ig NES Flag	Flag
							-
00409004010	KETAMINE HCL 100mg/mL VIAL 10 X 5 ML VIAL MUV, OUTER	KETAMINE HCL VIAL	HOSPIRA-NOVAP	U Y			



Supply assurance

In specific reports, such as Contract Optimization, you can identify NDCs associated with our Novaplus, Novaplus Enhanced Supply (NES), and NES-Reserve programs.

novaplus^{-;-}

- Highest rated private label
- Market-leading financial value
- Two labels to serve all members
- Higher fill rates for Vizient members
- 80% compliance earns rebates

972+ NDCs



novaplus⁻⁺⁻

Enhanced Supply

All the value of Novaplus, AND

- Up to 6-month additional inventory
- · Prioritizes essential medications
- Pooled inventory based on Vizient members' total historical purchases
- Protects entire pharmacy
- Purchasing NES NDCs drives additional inventory
- 80% compliance earns rebates

507+ NDCs

novaplus⁺ Enhanced Supply Reserve

All the value of NES, AND

- Dedicated inventory based on member's total historical purchases
- Increased savings over NES via higher rebates
- Expanded Failure-to-Supply accounts for indirect shortage costs, such as labor
- 90% compliance earns rebates
- Member enrollment process

270+ NDCs

Supply Assurance Advanced Access Hub

From the portal, you can also access the Advanced Access Hub

- Transparency into additional inventory for essential medications
- Inventory-related metrics and insights

Vizient Advanced Access Hub	Total Requests 24	My Request Status Open Requests 16 Closed Requests 6 Needs Attention 2	NES Inventory Additional Units for NES Program Inventory Cost Avoidance \$181,774
Place A New Request		View All Requests	NES Inventory Details



Advanced Analytics

- Spend analysis including spend overview dashboard
- Drug analysis including drug conversion opportunities

rmacy Systems/Facilities Selecti	FSM Demo Parent - acrossa FSM Demo Parent - x		Monitor	Тоо	olbox						
View ~					8	Explore ~ 🕑 Text box	🕤 Shapes 🗸 I	🖓 Buttons ~	C Visual	l interactions ~	C Re
System PSM Demo Parent - 327 Spend by The	Spend Analysis 70653 erapeutic Class Enhanced a n Contract @Net Contract Automotation	Facility All	(Y Start Date Y Mar-2023	 ✓ End Dat ✓ Feb-2024 		 ■ Build ■ Eliters 	In E In E A K K K K V C C C V C C C C C V C C C C C V C C C C C C V C C C C C C V C C C C C C C V C C C C C C C V C C C C C C C C V C C C C C C C C C V C C C C C C C C C C C C C C C C C C C		Data	c Line It ade ype Substa n Detail
Analges	Biologicals Respiratory Therapy Agents Hematological Agents Endocrine Anti-Infective Agents sic, Anti-Inflammatory or Antipyretic						Keep		s here	> 🖶 NDC > 🚍 Price Verif	cation
Analges	Biologicals Respiratory Therapy Agents Hematological Agents Endocrine Anti-Infective Agents	S OM S	50M \$ 100M	S 150M		\$ 200M	Keep	o all filters			cation
	Biologicals Respiratory Therapy Agents Hematological Agents Endocrine Anti-Infective Agents aic, Anti-Inflammatory or Antipyretic	S OM S	50M \$ 100M			\$ 200M	Keep	o all filters			cation
Spend by Mo	Biologicals Respiratory Therapy Agents Hematological Agents Endocrine Anti-Infective Agents aic, Anti-Inflammatory or Antipyretic	S OM S	11.				Keep	o all filters			cation
	Biologicals Respiratory Therapy Agents Hematological Agents Endocrine Anti-Infective Agents aic, Anti-Inflammatory or Antipyretic	S OM S	Distributor Name	Spend S	Sold Quantity A	Average Price	Keep	o all filters			cation
Spend by Mo	Biologicale Respiratory Therap / Aperls Hematological Aperls Endocrine Anti-Internet-in Aperls sic, Anti-Inflammatory or Antipyretic	5 OM 5	Distributor Name Cardinal SPD Cardinal Health Inc McKesson Plasma and Biologics	Spend S \$ 256,461,898 \$ \$ 203,135,905 \$ \$ 50,657,922 \$	Sold Quantity 89,838 1,600,939 191,664	Average Price \$2,876.98 \$126.89 \$264.31	Keep	o all filters			cation
Spend by Mo	Biologicale Respiratory Therap / Aperls Hematological Aperls Endocrine Anti-Internet-in Aperls sic, Anti-Inflammatory or Antipyretic	S OM S	Distributor Name Cardinal SPD Cardinal Health Inc McKesson Plasma and Biologics CuraScript Specialty Distribution	Spend S \$ 258,461,898 \$ \$ 203,135,905 \$ \$ 50,657,922 \$ \$ 11,447,789	Sold Quantity A 89,838 1,600,939 191,664 616	Average Price \$2,876.98 \$126.89 \$264.31 \$18,584.07	Keep	o all filters			cation
Spend by Mo	Biologicals Respiratory Through Agents Hemotological Agents Endocrome Antelfactice Agents acc, Anti-inflammatory or Anlipyretic		Distributor Name Cardinal SPD Cardinal Health Inc McKesson Plasma and Biologics	Spend S \$ 256,461,898 \$ \$ 203,135,905 \$ \$ 50,657,922 \$	Sold Quantity 89,838 1,600,939 191,664	Average Price \$2,876.98 \$126.89 \$264.31	Keep	o all filters			cation
Spend by Mo	Elobgicals Respiratory Through Agents Hemotological Agents Endocrine Analinterice Agents acc, Anti-inflammatory of Anlipyretic onth 5 6654 5 4545 5 4545 5 4545 5 4	944	Distributor Name Cardinal SPD Cardinal Health Inc McKesson Pasma and Biologos CaraScript Specialty Distribution ASD HealthCare Americaneer/Bernem	Spend S \$ 258,461,888 \$ 203,135,905 \$ 505,657,922 \$ 11,447,789 \$ 510,399,652 \$ 4,435,215	Sold Quantity A 89,838 1,600,939 191,664 616 3,256 49,606	Average Price \$2,876.98 \$126.89 \$264.31 \$18,584.07	Keep	o all filters			cation
Spend by Mo S 5704 S 6004 S 5004 S 5004	Biologicals Respiratory Through Agents Hemotological Agents Endocrome Antelfactice Agents acc, Anti-inflammatory or Anlipyretic	DM 544M 5.4	Distributor Name Cardinal SPD Cardinal Health Inc McKesson Pasma and Biologos CaraScript Specialty Distribution ASD HealthCare Americaneer/Bernem	Spend S \$ 258,461,898 \$ \$ 203,135,905 \$ \$ 50,657,922 \$ \$ 11,447,789 \$ \$ 10,399,652 \$	Sold Quantity 89,838 1,600,939 191,664 616 3,256	Average Price \$2,876.98 \$126.89 \$264.31 \$18,584.07 \$3,194.00	Keep	o all filters			cation
Spend by Mo \$ 5000 \$ 6000 \$ 5000 \$ 4000 \$ 4400	Biologicals Respiratory Therapy Agents Hematological Agents Enforcime And hethecke Agents sic. Anti-inflammatory of Antipyretic	5444 5444 544 5394 544 5394	Distributor Name Cardinal SPD Cardinal Health Inc McKesson Plasma and Biologics Cardiscipt Specially Detribution ASD Healthcare AnderstoraceBergen M	Spend S \$ 258,461,888 \$ 203,135,905 \$ 505,657,922 \$ 11,447,789 \$ 510,399,652 \$ 4,435,215	Sold Quantity A 89,838 1,600,939 191,664 616 3,256 49,606	Average Price \$2,876.98 \$126.89 \$264.31 \$18,584.07 \$3,194.00 \$89,41	Keep	o all filters			cation
Spend by Mo \$ 5000 \$ 6000 \$ 5000 \$ 4000 \$ 4400	Biologicals Respiratory Therapy Agents Hematological Agents Enforcime And hethecke Agents sic. Anti-inflammatory of Antipyretic	5444 5444 544 5394 544 5394	Distributor Name Cardinal SPD Cardinal Health Inc McKesson Plasma and Biologics CaraScript Specialty Distribution ASD Healthcare AmeriscurceBrignn Qu/A Pharmaceuticals	Spend S \$ 258,461,888 \$ 203,135,905 \$ 506,657,922 \$ 11,447,789 \$ 10,399,652 \$ 4,435,215 \$ 1,105,115 \$ 1,05,115	Sold Quantity A 89,838 1,600,939 1191,664 616 3,256 49,606 7,1167 7	Average Price \$2,876.98 \$126.89 \$2264.31 \$18,584.07 \$3,194.00 \$89.41 \$15.53	Keep	o all filters			cation
Spend by Mo \$ 5000 \$ 6000 \$ 5000 \$ 4000 \$ 4400	Elobgicals Respiratory Through Agents Hemotological Agents Endocrine Analinterice Agents acc, Anti-inflammatory of Anlipyretic onth 5 6654 5 4545 5 4545 5 4545 5 4	5444 5444 544 5394 544 5394	Distributor Name Cardinal SPD Cardinal Health Inc McKosson Paama and Biologos CuraScipt Specially Distribution ASD Healthcare Montification CuraScipt Application Cardinal Application Cardinal Health Inc Correscipt Specially Distribution ASD Healthcare Corresciption CuraSciption Corresciption CuraSciption Corresciption CuraSciption Corresciption CuraSciption CuraSciption Corresciption CuraSciption CuraSciptio	Spend S \$ 258,461,898 \$ \$ 203,135,905 \$ \$ 50,657,922 \$ \$ 11,447,789 \$ \$ 10,399,652 \$ \$ 4,435,215 \$ \$ 1,105,115 \$	Sold Quantity A 89,838 1,600,939 1191,664 616 3,256 49,606 71,167 1,124	Average Price \$2,876.98 \$126.89 \$284.31 \$18,584.07 \$3,194.00 \$89.41 \$15.53 \$26.77	Keep	o all filters			cation

Drug Budget Forecast report

Available to all organizations that participate in the Vizient pharmacy program

Personalizes the projections from the Pharmacy Market Outlook with your own spend data

- High level projection
 analysis and overview
- Detailed report with data filters and dynamic fields
- Editable within portal and exportable

System		Timeframe	e				
PSM Demo Parent - 3270653		✓ Feb-2023 -	Jan-2024	\sim			
	_						
Overview	Details						
Total Spend	Analyzed Spend	Analyzed Spend %	6 Projected Inflation	on ¹⁰ Project	ted Inflation %	Projected Analyzed Spend	Total Projected Spend
\$ 534,892,999	\$ 467,381,271	87.4 %	\$ 17,820,51	6	3.8 %	\$ 485,201,787	\$ 552,629,453
View Top 10 \checkmark by	y Therapeutic Class Enh	anced 🗸				Total Spend	Inflation Impact
			Projected Inflation Impact	Analyzed Spend	Projected Inflation %	Total Spend Projected Analyzed Spend	· · · · ·
herapeutic Class Enhanced			Projected Inflation Impact \$ 6,667,174	Analyzed Spend \$ 181,540,221	Projected Inflation %	Projected Analyzed Spend	· · · · ·
herapeutic Class Enhanced	Total Spend	My % of Total Spend			-	Projected Analyzed Spend \$ 188,207,395	Total Projected Spend
herapeutic Class Enhanced ntineoplastics espiratory Therapy Agents	Total Spend \$ 187,311,476	My % of Total Spend 35.0 %	\$ 6,667,174	\$ 181,540,221	3.7 %	Projected Analyzed Spend \$ 188,207,395 \$ 55,691,324	Total Projected Spend \$ 193,978,650
herapeutic Class Enhanced ntineoplastics espiratory Therapy Agents iologicals	Total Spend \$ 187,311,476 \$ 58,581,089	My % of Total Spend 35.0 % 11.0 %	\$ 6,667,174 \$ 2,734,542	\$ 181,540,221 \$ 52,956,782	3.7 % 5.2 %	Projected Analyzed Spend \$ 188,207,395 \$ 55,691,324 \$ 44,730,569	Total Projected Spend \$ 193,978,650 \$ 61,231,569
herapeutic Class Enhanced ntineoplastics espiratory Therapy Agents iologicals ematological Agents	Total Spend \$ 187,311,476 \$ 58,581,089 \$ 54,279,197	My % of Total Spend 35.0 % 11.0 % 10.1 %	\$ 6,667,174 \$ 2,734,542 \$ 1,830,480	\$ 181,540,221 \$ 52,956,782 \$ 42,900,089	3.7 % 5.2 % 4.3 %	Projected Analyzed Spend \$ 188,207,395 \$ 55,691,324 \$ 44,730,569 \$ 41,863,263	Total Projected Spend \$ 193,978,650 \$ 61,231,569 \$ 56,109,677
herapeutic Class Enhanced Intineoplastics Respiratory Therapy Agents iologicals Iematological Agents Indocrine	Total Spend \$ 187,311,476 \$ 58,581,089 \$ 54,279,197 \$ 48,391,296	My % of Total Spend 35.0 % 11.0 % 10.1 % 9.0 %	\$ 6,667,174 \$ 2,734,542 \$ 1,830,480 \$ 888,486	\$ 181,540,221 \$ 52,956,782 \$ 42,900,089 \$ 40,974,778	3.7 % 5.2 % 4.3 % 2.2 %	Projected Analyzed Spend \$ 188,207,395 \$ 55,691,324 \$ 44,730,569 \$ 41,863,263 \$ 33,955,178	Total Projected Spend \$ 193,978,650 \$ 61,231,569 \$ 56,109,677 \$ 49,279,781
View Top 10 v by Interapeutic Class Enhanced Antineoplastics Respiratory Therapy Agents Biologicals termatological Agents Endocrine Anti-Infortive Agents Analgesic, Anti-Inflammatory or nitypretic	Total Spend \$ 187,311,476 \$ 58,581,089 \$ 54,279,197 \$ 48,391,296 \$ 36,743,366 \$ 22,706,531	My % of Total Spend 35.0 % 11.0 % 10.1 % 9.0 % 6.9 % 4.2 %	\$ 6,667,174 \$ 2,734,542 \$ 1,830,480 \$ 888,486 \$ 1,402,440	\$ 181,540,221 \$ 52,956,782 \$ 42,900,089 \$ 40,974,778 \$ 32,552,737	3.7 % 5.2 % 4.3 % 2.2 % 4.3 %	Projected Analyzed Spend \$ 188,207,395 \$ 55,691,324 \$ 44,730,569 \$ 41,863,263 \$ 33,955,178 \$ 18,535,953	Total Projected Spend \$ 193,978,650 \$ 61,231,569 \$ 56,109,677 \$ 49,279,781 \$ 38,145,806



Current insights





Price Changes through February 2024


Contract Drug Price Increase/Decrease				Contract Dru ce increase/Decreas				erall Drug		
Contract drugs are those drugs that are under Vizient GPO, and thus under certain price o communication contractual guidelin	control and	No C		ose drugs that are N and thus had no pric ion contractual guid	ing control or	The o		H Contract and No C rease/decrease.	ontract drug	
Net Impact of Drug Price Changes %	6 of Total Spe	nd Ne	t Impact of Drug Pr	ice Changes	Net Im	Net Impact of Drug Price Changes % of Total Spend				
Historical Tracker							Table	\$ Chart	% Chart	
	2023	Jul-2023	Aug-2023	Sep-2023	Oct-2023	Nov-2023	Dec-2023	Jan-2024	Feb-2024	
Annualized Spend	607,880,340	\$127,198,083,336	\$144,535,841,810	\$127,033,390,945	\$143,715,016,729	\$144,685,603,535	\$143,367,716,940	\$139,661,790,056	\$137,115,436,37	
Annualized Contract Price Changes	(\$686,823)	+\$10,952,307	(\$1,651,723)	(\$4,317,103)	+\$73,767,032	+\$26,354,878	(\$3,374,326)	+\$316,817,979	(\$28,166,036	
Annualized No Contract Price Changes	\$64,034,814	+\$159,219,263	+\$1,068,955	+\$20,038,634	(\$266,768)	+\$11,982,619	+\$16,955,360	+\$1,158,967,594	+\$18,798,27	
Annualized Total Price Changes	\$63,347,991	+\$170,171,569	(\$582,768)	+\$15,721,530	+\$73,500,264	+\$38,337,498	+\$13,581,033	+\$1,475,785,573	(\$9,367,766	
% Change	+0.05 %	+0.13 %	(0.00 %)	+0.01 %	+0.05 %	+0.03 %	+0.01 %	+1.06 %	(0.01 %	
Historical Tracker - Net Price	Change						Table	\$ Chart	% Chart	
● Contract ● No Contract ● Overall +S2bn										
+\$2011								+\$1,475,785,573		
+\$1bn										
+\$26,946,740 (\$574,762)	+\$7,693,56	4 +\$63,347,991	+\$170,171,569	(\$582,768) +\$15	5,721,530 +\$73,50	0,264 +\$38,337,4	498 +\$13,581,033		(\$9,367,766)	

Price quantity mix insights

Jan. to June 2023

versus

July to Dec. 2023



Price quantity mix insights

Baseline Identified Spend \$34,175,228,358 Sep-2023 - Nov-2023: Comparative Identified Spe... \$34,182,244,212 \$277,881,735 \$444,058,519 \$195,494,160 \$19,512,865 Total PQM Impact +\$7.015.854 Price Quantity Started Buying Stopped Buying +\$2.562.689.665 21,511 NDCs with Spend Increase of 18,000 NDCs with Spend Decrease of (\$2,555,673,810) Brand Name Total PQM Impact Price Change Qty Change Started Buying Stopped Buying Total Spend Total Spend Sep-2023 - Nov-2023 Dec-2023 - Feb-2024 **OZEMPIC** +\$115 124 953 +\$10.281.503 +\$104 850 008 (\$6,550) \$2 283 850 010 NORDITROPIN FLEXPRO +\$74,734,178 +\$32,194,540 +\$42,539,639 HUMIRA(CF) PEN \$2.097.792.058 VEKLURY +\$67.312.523 +\$6.306.360 +\$61.006.167 \$1,551,251,549 STELARA \$1,422,545,841 ZEPBOUND +\$55.462.035 +\$55.482.956 (\$20.922) \$734,755,400 SKYRIZI PEN TREMFYA (\$76,426,941) +\$1.071.921 (\$77,498,861) \$526.533.439 TRULICITY (\$85,372,646) (\$1,103,583) (\$84,269,062) \$453,493,943 TREMFYA \$377,067,002 OTEZLA (\$88,441,140) (\$20.029.079) (\$68,412,062) \$373.668.058 OTEZLA \$285 226 917 STELARA (\$128,705,708) +\$11.165.330 (\$139.871.034) \$297.461.273 HUMIRA(CF) PEN OZEMPIC (\$186,057,952) (\$30.496.466) (\$155,561,506) \$412,586,226 SKYRIZI PEN (\$208.221.961) +\$2.002.039 (\$210.224.001) \$245,838,221 TRULICIT \$160,465,575 Total (\$460.592.659) +\$11,371,644 (\$471,957,756) (\$6.550)\$131,891,617 VEKLURY \$199,204,140 \$61,056,766 NORDITROPIN FLEXPRO \$135,790,944 \$903.628 ZEPBOUND \$56.365.663

Sept. to Nov. 2023

versus

Dec. 2023 to Feb. 2024

Price quantity mix insights Drill down to therapeutic class

Sept. to Nov. 2023

versus

Dec 2023 to Feb 2024

View Top 10 🗸 by Th	herapeutic Class En	hanced \checkmark fo	r All NDC's		Vie	w Details					Dec. 2023	to Feb. 202
					₹ 63					_		
Therapeutic Class Enhanced	Total PQM Impact	Price Change	Qty Change	Started Buying	Stopped Buying		Total Spend		Total Spend			
Antineoplastics	+\$307,944,378	+\$149,757,805	+\$135,149,480	+\$27,228,339	(\$4,191,231)	Se	p-2023 - Nov-202	23 De	ec-2023 - Feb-202	24		
Endocrine	+\$179,013,895	(\$24,404,289)	+\$176,707,714	+\$28,839,756	(\$2,126,900)							
Cardiovascular Therapy Agents	+\$158,408,387	+\$44,741,165	+\$60,779,744	+\$53,098,405	(\$210,911)							
Gastrointestinal Therapy Agents	+\$98,669,846	+\$17,455,041	+\$68,667,865	+\$12 722 505	(\$175.577							
Anti-Infective Agents	+\$84,525,292	+\$25,846,807	+\$53,095,506	Generic Name		Total PQM Impact	Price Change	Qty Change	Started Buying	Stopped Buying	Total Spend	Total Spend
Hematological Agents	+\$60,536,510	+\$16,742,146	+\$37,881,296	SOMATROPIN		+\$134,805,532	+\$52,295,370	+\$82,510,615		(\$449)	Sep-2023 - Nov-2023	Dec-2023 - Feb-2024
Locomotor System	+\$59,842,304	+\$19,692,871	+\$39,776,533	SEMAGLUTIDE		+\$118,358,376	+\$11,453,844	+\$106,911,089		(\$6,550)	SEMAGLUTIDE	\$355,080,623 \$473,438,999
Biologicals	(\$223,808,852)	+\$10,136,993	(\$242,346,824)	TAFAMIDIS		+\$42,937,395	+\$10,933,759				DULAGLUTIDE	\$245,838,221
Analgesic, Anti-inflammatory or	(\$444,997,147)	(\$77,654,859)	(\$372,096,504	EMPAGLIFLOZIN		+\$15,684,211	+\$2,701,662				5404 01 151 0711	\$160,465,575 \$239,264,591
Antipyretic				TEPROTUMUMAE		+\$13,399,127	+\$7,423,016				EMPAGLIFLOZIN	\$254,948,802
Dermatological	(\$461,713,904)	+\$49,487,088	(\$511,554,372)	OCTREOTIDE ACI MICROSPHERES	ETATE,	+\$13,357,940	+\$3,196,310	+\$10,161,629			TAFAMIDIS	\$177,025,912 \$219,963,307
Total	(\$181,579,293)	+\$231,800,767	(\$553,939,561)	INSULIN ASPART		(\$18,496,377)	(\$17,950,850)	(\$545,519)			INSULIN LISPRO	\$167,257,594 \$102,582,104
				INSULIN GLARGIN RECOMBINANT A		(\$23,364,058)	(\$29,868,663)	+\$6,498,243	+\$6,356		SOMATROPIN	\$151,158,666 \$285,964,197
				INSULIN LISPRO		(\$64,675,490)	(\$64,317,866)	(\$357,619)			TEPROTUMUMAB-TRBW	\$117,098,733 \$130,497,860
				DULAGLUTIDE		(\$85,372,646)	(\$1,103,583)	(\$84,269,062)				\$111.593.291
				Total		+\$146,634,008	(\$25,237,001)	+\$171,871,671	+\$6,356	(\$6,999)	INSULIN GLARGINE, HU	\$88,229,233
											OCTREOTIDE ACETAT	\$74,247,839 \$87,605,779
											INSULIN ASPART	\$43,639,834 \$25,143,456

Pharmacy Analytics Rx GPO participant vs. Subscription

Explore	Membership	Subscription
Benchmark Opportunities		٠
Price Leveling		٠
Price Change Impact Insights		٠
Contract Optimization	٠	٠
Drug Shortage Report Insights	٠	٠

Monitor	Membership	Subscription
Spend Overview Trends	٠	٠
Market Share Optimization		٠
Drug Budget Forecast	٠	٠
Price Quantity Mix		٠
Essential Medication Insights	٠	٠
Controlled Substance Insights		٠
Failure to Supply Insights	٠	٠
Price Verification Insights	٠	٠
CMS Outpatient Reimbursement		٠

Resource	Membership	Subscription
Consultant		•

Toolbox	Membership	Subscription
Advance Analytics		٠
Benchmark Price Performance		٠
Benchmark Line-Item Detail		٠
Peer Compare Insights		٠
Pharmacy Spend Reports		٠
Hazardous Drug Insights	٠	٠
Advanced Drug Analysis		٠
Anesthesia Gases Report	•	٠
Biosimilar Conversion Trends		٠
High Dose IV Iron Trends		•

Price Verification services	Membership	Subscription
Non-contract to contract	٠	٠
Contract to contract		•
Tier		٠
DSH		•

Pharmacy Learning Center

Register for instructor-led and access learning resources

- Pharmacy Analytics
- Pharmacy Value Tracker (PVT)
- Advanced Access Hub
- Site of Care Database

Contact PharmacyQuestions@vizientinc.com

Welcome This center pro Analytics, Pha led sessions u	vides access to learning resources a macy Value Tracker (PVT), Vizieri As sing the upcoming events calendar.	uch as user manuals, job aids and e-learnin twanced Access Hub and Site of Care Data	ase. Register for in	istructor-
Pharmacy Analytics Pharmacy	Upcoming Events Search this site CCESSEd Transcy Portal New Thereasy Portal Thereasy Portal Thereasy Portal International paper to on they have thereasy clinical, centered, performance,	Upcoming events Tor Neighting the new Pharmacy Portal and Pharmacy Analytics platform with PAD projections and data NEW Pharmacy Analytics Training	All ev 3/27/2024 1:00 PM 3/28/2024 2:00 PM	the Experts ents are in Central Tin Brd Time 3/27/2024 2:00 PM 3/28/2024 3:00 PM
Pharmacy Value Tracker (PVT) Accel Vizient Advanced Quick	spulatory metrics and key performance thrs (KPIs) se Guide 2 Start Guide - Coming soon iew (E-Learning) - Coming soon Access	NEW Pharmacy Analytics Training NEW Pharmacy Analytics Training NEW Pharmacy Analytics Training NEW Pharmacy Analytics Training Pharmacy Pottal and Pharmacy Analytics Overview Pharmacy Analytics Additional Insights (Part 1) Explore & Montori Pharmacy Pottal and Pharmacy Analytics Overview	4/1/2024 2:00 PM 4/3/2024 2:00 PM 4/5/2024 10:00 AM 4/10/2024 3:00 PM 4/17/2024 3:00 PM	3/29/2024 11:00 AA 4/1/2024 3:00 PM 4/3/2024 3:00 PM 4/5/2024 11:00 AM 4/10/2024 4:00 PM 4/17/2024 4:00 PM 4/24/2024 11:00 AA
	g the Pharmacy E		Next •	4/24/2024 4:00 PM

vizientinc.com/learning-center/pharmacy-analytics-resources





- Real-time purchasing oversight
- Ability to customize views and schedule reports
- Insights and reporting into drug shortages, controlled medication, essential medications, biosimilars and more
- Data down to invoice level detail for a rolling 24 months

Vizient Pharmacy Analytics Formerly Savings Actualyzer – Pharmacy (VSAP)

Now available!

- **Pharmacy Portal**: New user-friendly interface allowing a singular access point for pharmacy services and reporting
- **Pharmacy Analytics**: Available from the Pharmacy Portal with a new look and capabilities in addition to your favorite existing reports

Training: Experience the new tools and ask questions of our analytics experts



Select a session that works for you

vizientinc.com/learningcenter/pharmacy-analytics-resources **Webinar**: Insights into emerging trends and success stories for Pharmacy Analytics

May 14, 1-2pm CT





Contact PharmacyQuestions@vizientinc.com



Next steps

- Explore Pharmacy Portal and Pharmacy Analytics
- If you need access, email vizientsupport@vizientinc.com
- Register for training sessions
- If interested in learning more, email: <u>richard.ponder@vizientinc.com</u>



Questions?





Pharmacy program resources



Gain expert insights for pharmacy planning A webinar series exploring new and hot topics from the recently published Pharmacy Market Outlook

Navigating Vizient Pharmacy Analytics with PMO projections and data

March 27, 1 p.m. CT

Learn about the features and benefits of our new Pharmacy Portal and rebranded Pharmacy Analytics platform (formerly Vizient Savings Actualyzer – Pharmacy)

TODAY!

Cell & gene therapy and specialty pharmaceuticals

April 24, 1 p.m. CT

There are 170+ gene and cellular immunotherapy products in the pipeline.

Find out more about the novelty of gene therapy and the challenges it presents






vizient

Learn more and register at vizientinc.com/events

Access and download



Visit the Pharmacy Market Outlook webpage where you can access and download the report as well as



info.vizientinc.com/ pharmacy-marketoutlook-memberdetails

Contact PharmacyQuestions@vizientinc.com

Also from this page...

Access the latest Budget Impact **Projections** report related to the healthcare supply chain



vizien





Read our new trends report and learn about strategies to grow revenue



Helpful communications

Pharmacy Hot Info	Weekly newsletter with contract price changes, advocacy updates, upcoming webinars
Pharmacy Monitor	Monthly clinical insights
Pharmacy Sourcing Forum call	 Third Wednesday of every month Contract updates and other important news related to vaccines, drug shortages, product access
Pharmacy Institute	Pharmacy Solutions training and overview for new members or individuals new to their role
VerifiedRx	 Pharmacy podcast with the latest news to support the strategic role of pharmacy New episodes second Tuesday of each month

vizient

Contact us at PharmacyQuestions@vizientinc.com

We are here to help



Pharmacy Solutions

Sourcing, clinical and ambulatory support





Drug spend and clinical analytics platform



Operations, ambulatory, 340B, clinical



Aggregation Groups

Pharmacy purchasing groups & oncology network

Contact us at PharmacyQuestions@vizientinc.com



Let's work together

vizient

Contact <u>PharmacyQuestions@vizientinc.com</u> for more information

This information is proprietary and highly confidential. Any unauthorized dissemination, distribution or copying is strictly prohibited. Any violation of this prohibition may be subject to penalties and recourse under the law. Copyright 2024 Vizient, Inc. All rights reserved.